参考文献/References:
[1] Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2018,20(5): 853-872.
[2] Chatterjee S, Khunti K,Davies MJ. Type 2 diabetes[J]. Lancet,2017,389(10085): 2239-2251.
[3] Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update[J]. Circulation, 2019,140(7): e294-e324.
[4] Yu Y,Gupta A,Wu C,et al. Characteristics, management, and outcomes of patients hospitalized for heart failure in China: The China PEACE Retrospective Heart Failure Study[J]. J Am Heart Assoc,2019,8(17):e012884.
[5] Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry[J]. Am Heart J,2016,182:9-20.
[6] Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J]. B MJ,2000,321(7258):405-412.
[7] Metra M, Teerlink JR. Heart failure[J]. Lancet, 2017,390(10106):1981-1995.
[8] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016,18(8):891-975.
[9] Bell DSH, Goncalves E. Heart failure in the patient with diabetes: epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications[J]. Diabetes Obes Metab, 2019,21(6):1277-1290.
[10] Ajam T, Ajam S, Devaraj S, et al. Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction[J]. Am Heart J,2018,199:1-6.
[11] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[12] Kristensen SL, Preiss D, Jhund PS, et al.Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial[J]. Circ Heart Fail,2016,9(1):1-12.
[13] Komajda M, Tavazzi L, Francq BG, et al .Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial[J]. Eur J Heart Fail, 2015,17(12):1294-301,
[14] Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes[J]. N Engl J Med,2014,371(15):1392-1406.
[15] Rodriguez-Gutierrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence[J]. Circ Cardiovasc Qual Outcomes, 2016,9(5):504-512.
[16] Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial[J]. Lancet,2005,366(9493): 1279-1289.
[17] Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy[J]. Lancet,2015,385(9982):2107-2117.
[18]Roumie CL, Min JY, D’Agostino McGowan L, et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study[J]. J Am Heart Assoc, 2017,6(4):e005379.
[19] Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis[J]. JAMA,2018,319(15):1580-1591.
[20] Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial[J]. JAMA,2019,Sep 19. DOI : 10.1001/jama.2019.13772 [Epub ahead of print].
[21] Patorno E, Schneeweiss S, Gopalakrishnan C, et al. Using real-world data to predict findings of an ongoing phase Ⅳ cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride[J]. Diabetes Care,2019,42(12):2204-2210.
[22] Gerstein HC, Jung H, Ryden L, et al. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)[J]. Circulation,2018,137(1):88-90.
[23] Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol,2019,7(10):776-785.
[24] von Scholten BJ, Persson F, Rosenlund S, et al. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial[J]. Diabetes Obes Metab,2017,19(6):901-905.
[25] Jojima T,Uchida K,Akimoto K,et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice[J]. Atherosclerosis,2017,261:44-51.
[26] Romero SP, Andrey JL, Garcia-Egido A, et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community[J]. Int J Cardiol,2013,166(2):404-412.
[27] Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients[J]. Circ Heart Fail,2013,6(3):395-402.
[28] 高斯德,李卫萍,李虹伟.钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展[J].心血管病学进展,2018,39(5):703-708.
[29] Fitchett D,Inzucchi SE,Wanner C,et al. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(R) trial[J]. Eur Heart J, 2020,41(2):209-217.
[30] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[31] Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs(CVD-REAL Nordic): a multinational observational analysis[J]. Lancet Diabetes Endocrinol,2017,5(9):709-717.
[32] Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 Study[J]. J Am Coll Cardiol, 2018,71(23):2628-2639.
[33] Abraham WT,Ponikowski P,Brueckmann M,et al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure[J]. Eur J Heart Fail,2019,21(7):932-942.
[34] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,140(18):1463-1476.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(5):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(5):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[5]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[6]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[7]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[8]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(5):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[9]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[10]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]